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In many species, genes controlling specific immune responses are linked to the
major histocompatibility complex (MHC) (1). The bulk of available evidence
indicates that these genes are expressed in T lymphocytes (1), although some
data suggest expression at the B-cell level (2, 3). It has been postulated (4) that
the MHC-linked immune response (Ir) genes code for the T-cell receptor for
antigen, although other models of Ir-gene function have been proposed which do
not invoke antigen recognition properties of these gene products (5).
In the mouse, the MHC-linked Ir genes have been mapped to the I
chromosomalsegment, which lies between the Kand S regions (6). Ithasrecently
been shown that the I region codes for surface antigens on both T and B
lymphocytes (7-10) . These I-region-associated (Ia) antigens might represent
products of the Ir genes. The la antigens have been studied by complement
(C)-mediated cytotoxicity (7), stimulation in the mixed lymphocyte reaction
(MLR) (11), autoradiography (10), and immunofluorescence (12).
Yet another approach to the study of cell surface antigens involves the
transplantation behavior of neoplastic cell populations. In this report, we
describe the results of transplanting a series ofseven T-cell lymphomas, and one
mammary adenocarcinoma of congenic resistant strain origin.
Materials and Methods
Mice.
￿
A.TH, A.TL, B10.A(2R), and B10.A(4R) mice were progeny of breeding pairs obtained
from Dr. D. C. Shreffler, University of Michigan, Ann Arbor, Mich. Other mouse strains were from
The Walter and ElizaHall Institute stocks. Mice of either sexwere used at an age of approximately 8
wk. The H-2 and la specificities have been previously described (6).
Tumors.
￿
All tumors described in this paper arose spontaneously, and were generally detected
when a mouse was noted to have a visible subcutaneous lump (mammary adenocarcinoma), or
appeared ill andhad an enlarged spleen, or waskilled forother purposes. In all cases, specimenswere
processed for histology. Age and sex of tumor origin are given in Table II.
Characterization of Tumors.
￿
Cellsfrom tumor masses or tumor-infiltrated organs were tested for
membrane immunoglobulin by direct immunofluorescence and for Thy 1.2 antigen by indirect
immunofluorescence using anti-Thy 1.2 serum followed by fluorescein-labeled rabbit antimouse
gamma globulin. Cells from some lineswere also tested forthe presence ofreceptorsfortheFc portion
of IgG by a rosetting technique using antibody-coated sheep erythrocytes (13) .
*This is publication no. 2,090 from The Walter andEliza Hall Institute. This work wassupported
by research grants AI-0-3958and AM-11234 from the U. S. Public Health Service, and grants from the
National Health and Medical Research Council of Australia.
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Tumor Maintenance.
￿
Primary tumors were established andmaintained in serial transplantation
by subcutaneous or intravenous inoculation of dispersed cell suspensions (approximately 107 cells)
prepared from tumor involved tissues. Tumorlines are designated by the prefix WEHI andthe tumor
line number (205, 211, 213, 215, 216, 222, 223, and 228) . Experiments described in this paper involve
transplant generations from 1-10.
Experimental Design. Mice were injected with known numbers of viable tumor cells (eosin
exclusion), either subcutaneously in the flank or intravenously. They were then observed every 2-3
days for signs of tumor growth. At varying periods, depending on the rate of growth, the mice were
killed and the spleens and/or local subcutaneous tumor mass excised and weighed.
Results and Discussion
In the course of routine studies of la antigens, approximately500 A.TH and 300
A.TL mice were killed over an 18-mo period . During this time we have found 15
mice with lymphomas, of which 8 have so far proven transplantable, and 7 are
reported here . In addition, one A.TL mouse was found to have a mammary
adenocarcinoma . We are unable to give true tumor incidence figures, because
occasional animals in our colonies died without an autopsy being performed.
However, the figures given would represent a lower limit. The tumors occurred in
relatively young mice (6-42 wk) of either sex (Table II).
Macroscopically, all the lymphoma-bearing mice had very large spleens
(typically 3-4 g in weight) and enlarged lymph nodes in all areas, and most had
enlarged livers and obviously infiltrated kidneys. The thymus was macroscopi-
cally enlarged in approximately 50% of cases. The neoplastic cells had large,
irregular, lightly staining nuclei and scanty pale cytoplasm. Mitotic figures were
frequent. Histologically, there was very marked infiltration of lymph nodes,
spleen and liver, and patchy perivascular infiltration of kidney and lungs. All the
lymphomas were strongly positive for Thy 1.2 antigen and negative for high
density surface immunoglobulin, and are hence of T-cell origin . WEHI-211 and
WEHI-222 were tested for presence of Fc receptors and found to be negative.
Studies on la antigens as detected by anti-la serum are currently in progress.
The mammary tumor (WEHI-205), which arose in a pregnant mouse approxi-
mately 30 wk of age, consisted of a solitary cystic subcutaneous mass with no
evidence of metastasis. Histology showed moderate differentiation, with large
secretory follicles filled with eosinophilic material.
Upon transplantation into syngeneic recipients, marked differences in growth
patterns were observed (Tables I and 11). Tumors WEHI-205, 211, 213, and 223
grew subcutaneously, while the remainder grew exclusively by metastasis,
notably in the spleen. In general, there appeared to be an inverse correlation
between subcutaneous and splenic growth (Table 1) . The reason for such
differences is not known, but within each tumor line the observed differences in
growth patterns were quite consistent from one experiment to another.
When transplanted subcutaneously into congenic partner strains (Table 11),
the tumors were consistently rejected . On the other hand, when given intrave-
nously it was sometimes possible to overcome rejection. Whether this is merely a
dosage effect, or is due to some other mechanism, is unclear.
There could be several reasons for the failure of growth in congenic partner
strains. Firstly, the neoplastic cells could possess strong tumor-specific antigens,
for which the partner strains happen to be responders and the strain of origin538
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TABLE I
Growth of Subcutaneous Inocula of T Lymphomas in Syngeneic Mice
Tumor line Strain (donor
and recipient)
Tumor growth*
Localsubcutaneous$
￿
Spleen§
WEHI-216
￿
A.TL
￿
No local growth (0/9)
￿
9.1 f2.2
WEHI-215
￿
A.TH
￿
150 f 50 (0/16)
￿
5.5 t0.8
WEHI-213
￿
A.TH
￿
911 t 190 (17/17)
￿
2.5 t 0.4
All recipients given subcutaneous injection of 5 x 106 tumor cells (213, 215, and 223) or 15 x 10' (216) and
examined at 26 days.
$ Mean weights of excised tumor (milligrams t SEM.). Values in parentheses show number of mice/total with
increasing tumor growth.
§ Splenic tumor growth expressed as mean t SEM. ofratio ofspleen weights (milligrams per gram body weight) of
tumor injected/control mice.
TABLE II
Summary of T Lymphoma Growth in Congenic Resistant Inbred Strains
Incidence of successful tumor growth$
* Sex and age of mouse at time of primary tumor detection given in parentheses.
$ Donor cell inoculum varies from 5-20 x 10" and assay time from 8-20 days (both constant within a given
experiment). Successful growth scored as subcutaneous tumor nodule of >10 mm diameter or Splenic tumor
growth of greater than twofold spleen weight increase (based on milligrams per gram body weight). Values show
number of mice with successful tumor takes/number inoculated. Underlined values indicate clear strain specificity
oftumor takes.
WEHI-223 A.TH 1400 t 340 (4/4) 1 .4,0A
nonresponders. However, the H-2-linked Ir genes are dominant (1) and thus the
F1 hybrids between responders and nonresponderswill be responders. In the cases
where tumors were transplanted into A.TH x A.TL F1 hybrids, they grew as
rapidly as in Syngeneic hosts (Table III), indicating thatIr-gene effects relating to
tumor-specific transplantation antigens are unlikely to be the explanation.
Furthermore, this explanation would require the rather unlikely presence of an
A.TH tumor antigen to which A.TL mice were responders and a different A.TL
tumor antigen to which A.TH were responsive .
Secondly, the observed lack of growth could be due to differences at the TL
locus, at which A.TH and A.TL differ (14). This possibility is unlikely as there
are no Tla specificities on A.TL cellswhich are not shared by A.TH cells (14) and
yet A.TL tumors are rejected by A.TH mice. However, the possibilityofrejection
due to closely linked but distinct histocompatibility antigens controlled by the
TL region is not ruled out. In order to eliminate this possibility, A.TL cells
Tumor
line
Origin
A.TH
local
Subcutaneous
A.TL
local
inoculation
A.TH
spleen
A.TL
spleen
Intravenous
A.TH
spleen
inoculation
A.TL
spleen
WEHI-211 ATH(M. 32 wk) 10/10 0/10 0/4 0/4 6/6 0/8
WEHI-213 A.TH(M. 15 wk) 17/17 0/6 8/17 0/6 4/5 NT
WEHI-215 A.TH(M. 11 wk) 0/20 0/16 18/19 0/10 10/12 7/9
WEHI-223 A.TH(F. 42 wk) 4/4 0/4 0/4 0/4 3/3 0/3
WEHI-216 ATL(F. 36 wk) 0/9 0/9 0/9 9/9 _ 6/6 18/18
WEHI-222 A.TL(M. 34 wk) 0/10 0/7 1/10 6/7 4/12 7/7
WEHI-228 A.TL(M. 6 wk) 0/4 0/5 0/4 0/5 1/7 6/6GODING AND WARNER
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TABLE III
Transplantation in F, Hybrids
*Tumor mass from one A.TL mouse (approximately 2 g tissue) was dispersed by sieving into 10 ml
HEPES-buffered Eagle's medium, and clumps allowed to settle for 1 min. The supernate was decanted and
mixed thoroughly. Each animal received 0.5 ml subcutaneously. Animals were observed for 25 days. In positive
individuals, subcutaneous lumps approximately 2 cm in size were found, while in negative animals there was no
macroscopic growth.
t T lymphomas. 20 x 106 viable cells were injected subcutaneously.
§ T lymphoma. 8 x 106 viable cells injected subcutaneously. Similar growth patterns were seen with 2 x 106, 0.4 x
106, 0.1 x 106, and 0.025 x 106 cells.
(WEHI-216 and WEHI-222) were transplanted into A.TH x B10.D2 F, hybrid
mice (Table III). B10.D2 mice are Tlac and, as far as is known, are identical to
A.TL at H-2D and TL (14). Their clear rejection in these hybrids is thus unlikely
to be due to TL-region incompatibility. Although sex matching of tumor and
recipient was not possible in all experiments, no differences ascribable to the
H-Y antigen were detected.
The final possibility, which we favor, is that the tumors are rejected because
they possess Ia antigens. A.TH and A.TL mice differ at the Iregion and indeed
high titer antibodies against I-region products may be raised in both directions.
These antisera react strongly with B cells and weakly with T cells (9, 10) . It has
recently been shown that the Iregion isassociated with strong histocompatibility
effects as assessed by skin graft rejection (15). However, the presence of certain
antigens on skin cells is no guarantee that they will be expressed on other tissues.
In an attempt to more precisely map the I region responsible for rejection,
WEHI-216 (A.TL) tumor cells were transplanted into A.TH x B10.A(2R), A.TH
x B10.A(411), and A.TH x CBA F, hybrids (Table III). The results in the A.TH
x CBA recipients were erratic, with about halfthe mice having very large spleens
and the remaining half showing no evidence of tumor growth . There was rapid
growth in A.TH x B10.A(211) but not in A.TH x B10.A(411) recipients. From
present information onI-subregion assignment ofla specificities (6), the rejection
in A.TH x B10.A(411) F, mice could only be due to recognition of IC locus
determinants (specificity 7). An alternative possibility is the presence of as yet
Tumor Recipient Growth
Spleen weight/
body weight
(mg/g; 21 days)
WEHI-205* (mammary A.TL 20/20
adenocarcinoma) (A.TL) A.TH 0/30
A.TH x A.TL 7/7
WEHI-2161 (A.TL) A.TL 5/5 66.6 t 10.1
A.TH 0/4 5.3 t 0.4
A.TH x B10.A(2R) 4/5 49.0 f 17.2
A.TH x BIO.A(4R) 0/4 7.7 t 1 .9
A.TH x CBA 6/10 42.1+ 13.5
A.TH x B10.D2 0/5 4.8 t 0.2
WEHI-222$ (A.TL) A.TH x B10.D2 0/5 4.1 f 0.1
Subcutaneous tumor growth (mm t SE)
day 11 day 23
WEHI-211§ (A.TH) A.TH 3/3 4.3+0.9 21.0 t 1.0
A.TL 0/3 0 0
A.TH x A.TL 3/3 7.7 t 0.9 20.0 t 1.2540
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serologically undetected specificities determined by either the IB or IC locus.
The data imply that antigens controlled by the I region are present on T cells.
However, we cannot exclude the possibility that the cells are derepressed and
express la antigens that are not present on normal T cells. The results of
experiments involving transplantation of WEHI-205 (mammary adenocar-
cinoma) suggest that la antigens are also present on these cells. At least some la
antigens may be relatively widespread in their cellular distribution (16) . It also
seems likely that antigens controlled by different I subregions may have differing
distribution and function. Clear differences in susceptibility to viral-induced
oncogenesis have been shown to be linked to H-2 in the mouse, and are probably
due to Ir genes (1). Similarly, the association of certain viral and neoplastic
diseases with particular HL-A types may point to Ir-gene effects in humans . The
tumors may be useful in furthering the understanding of these problems, and in
the study of the possible relationship between the la antigens and the receptor for
antigen on T lymphocytes.
Summary
Seven spontaneously arising T-cell lymphomas originating in A.TH or A.TL
mice, which are congenic for the immune response gene (I) chromosomal segment
were described . When transplanted into partner strains which were incompatible
at the I region, the tumors were rapidly rejected. Rejection was proposed to be
due to the presence of antigens controlled by I-region genes .
We are grateful for the excellent technical assistance of Dianne Barr and Kathy Cruise.
Receiued for publication 24 March 1975.
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